ReviewIndian journal of ophthalmology2022
Myopia, its prevalence, current therapeutic strategy and recent developments: A Review.
Review in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06265454 (Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Management of myopia: a mini-review.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- 0.01% atropine combined with carteolol hydrochloride can inhibit the scleral remodeling in guinea pigs with form-deprivation myopia.Scientific reports · 2025Article
- Deep learning for predicting myopia severity classification method.Biomedical engineering online · 2025Article
- A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Access to Myopia Care in the United States-A Narrative Review.Investigative ophthalmology & visual science · 2025Review
- Review
- Uncovering predictors of myopia in youth: a secondary data analysis using a machine learning approach.Frontiers in medicine · 2025Article
- Curcumin modulated gut microbiota and alleviated renal fibrosis in 5/6 nephrectomy-induced chronic kidney disease rats.PloS one · 2025Article
- Development of risk prediction model for small incision lenticule extraction.Frontiers in medicine · 2025Article
- Investigation into the Therapeutic Efficacy and Inflammatory Modulatory Effects of the Combined Use of 0.01% Atropine Eye Drops and Orthokeratology Lenses in the Management of Myopia Among Adolescent Patients.Journal of inflammation research · 2025Article
- Uncorrected refractive errors, visual impairment and need for spectacles among children and adolescents in eastern, China.PloS one · 2025Article
- Myopia in Children: Epidemiology, Genetics, and Emerging Therapies for Treatment and Prevention.Children (Basel, Switzerland) · 2024Review
- Prevalence, sociodemographic risk factors, and coverage of myopia correction among adolescent students in the central region of Portugal.BMC public health · 2024Article
- Prevalence of Myopia Among Schoolchildren and the Impact of Increased Screen Time: A Systematic Review.Cureus · 2024Review
- Effects of Acute Mental Stress on Choroidal Thickness.Bioengineering (Basel, Switzerland) · 2024Article
- A study on the variability and correlation of ocular biological measurement parameters in adult myopic patients.Frontiers in medicine · 2024Article
- Repeated Low-Level Red-Light Therapy for Controlling Onset and Progression of Myopia-a Review.International journal of medical sciences · 2023Review
- Effectiveness of toric soft contact lenses for vision correction in patients with different degrees of astigmatism: a real-world study.International journal of ophthalmology · 2023Article
- Femtosecond-laser-assisted Small Incision Lenticule Extraction to Treat Refractive Error: A Narrative Review.Middle East African journal of ophthalmologyReview
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myopia is a widespread and complex refractive error in which a person's ability to see distant objects clearly is impaired. Its prevalence rate is increasing worldwide, and as per WHO, it is projected to increase from 22% in 2000 to 52% by 2050. It is more prevalent in developed, industrial areas and affects individuals of all ages. There are a number of treatments available for the control of myopia, such as glasses, contact lenses, laser surgery, and pharmaceuticals agents. However, these treatments are less beneficial and have significant side effects. A novel molecule, 7-methylxanthine (7-MX), has been found to be a highly beneficial alternate in the treatment of myopia and excessive eye elongation. Many preclinical and clinical studies showed that 7-MX is effective for the treatment of myopia and is presently under phase II of clinical investigation. We have also investigated preclinical toxicity studies such as acute, sub-acute, sub-chronic, and chronic on rats. In these studies, 7-MX was found to be non-toxic as compared to other reported anti-myopic agents. Moreover, as an ideal drug, 7-MX is observed to have no or low toxicity, brain permeability, non-allergic, higher oral administration efficacy, and low treatment costs and thus qualifies for the long-term treatment of myopia. This review article on 7-MX as an alternative to myopia treatment will highlight recent findings from well-designed preclinical and clinical trials and propose a potential future therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.